MIRAMAR, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Awaysis Capital, Inc. (OTCMARKETS: AWCA), a real estate management and hospitality company redefining residential resort living in emerging lifestyle destinations, today announced its participation at the upcoming Canada International Property Show, in partnership with Century 21 Belize (“C21 Belize”), a global real estate franchise company. The Canada International Property Show will be taking place October 31–November 1, 2025, at The Convention Centre in Miss ...

Core Insights - Solana Company has updated its holdings of Solana (SOL) tokens and cash as of October 29, 2025, reflecting its strategy to maximize SOL per share through disciplined asset management [1][2] Group 1: Holdings and Financials - As of October 29, the Company holds over 2.3 million SOL, an increase of approximately 1 million since the last update on October 6 [2] - The Company and its subsidiaries collectively hold more than $15 million in cash and stablecoins, which will be utilized to further its digital asset strategy [2] Group 2: Staking Performance - For October, the average gross staking yield was 7.03% APY, outperforming the stake-weighted average of the top 10 validators by approximately 36 basis points [3] - The staking yield generates consistent daily on-chain revenue while maintaining full liquidity and custody of the underlying assets [3] Group 3: Strategic Insights - The Company has increased its SOL holdings by roughly 5% in less than a month, with a gross staking yield exceeding 7% [4] - Institutional engagement with Solana Company has accelerated due to key network milestones and ecosystem developments, focusing on transparency and growth [4] Group 4: Market Position - Solana is recognized as one of the fastest-growing blockchain networks, processing over 3,500 transactions per second and maintaining approximately 3.7 million daily active wallets [4] - The network is a leader in transaction revenue and user adoption, offering an estimated 7% native staking yield, positioning SOL as a financially productive asset for long-term treasuries [4] Group 5: Company Overview - Solana Company, in partnership with Pantera Capital and Summer Capital, serves as a dedicated vehicle for institutional participation in the Solana ecosystem [5] - The Company's approach integrates capital markets access, on-chain management, and long-term staking to compound SOL-denominated returns [5]

Core Viewpoint - UFP Technologies, Inc. is set to report its third-quarter results on November 3, 2025, and will hold a conference call on November 4, 2025, at 8:30 AM ET to discuss these results [1][2]. Company Overview - UFP Technologies, Inc. is a contract development and manufacturing organization specializing in single-use and single-patient medical devices [3]. - The company plays a crucial role in the medical device supply chain and serves as a valued outsourcing partner for leading medical device manufacturers [3]. - Its products are utilized in various medical applications, including minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants [3].

Core Points - Creative Medical Technology Holdings, Inc. has entered into agreements for the immediate exercise of existing warrants to purchase up to 1,116,136 shares of common stock at an exercise price of $3.75 per share, expected to generate approximately $4.2 million in gross proceeds [1][4] - The company will issue new unregistered warrants for an aggregate of up to 2,790,340 shares at the same exercise price, with potential adjustments based on the lowest VWAP during a specified period [3] - The transaction is anticipated to close on or about October 29, 2025, subject to customary closing conditions, with proceeds intended for working capital and general corporate purposes [4] Financial Advisory - Roth Capital Partners is acting as the financial advisor for this transaction [2] Regulatory Compliance - The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933, with the company agreeing to file a registration statement with the SEC for the resale of shares [5]

Progress Data Platform now available on the premier AI procurement marketplace, helping agencies turn complex data into actionable intelligence BURLINGTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Progress Federal Solutions, a wholly owned subsidiary of Progress Software (Nasdaq: PRGS), today announced that it has achieved “Awardable” status through the Chief Digital and Artificial Intelligence Office’s (CDAO) Tradewinds Solutions Marketplace. This designation allows U.S. Department of Defense (DoD) custome ...

Core Insights - Rapid7, Inc. has introduced AI-generated risk intelligence and vulnerability intelligence capabilities to enhance security teams' ability to prioritize, collaborate, and remediate vulnerabilities more effectively [1][2][3] Group 1: AI-Generated Risk Intelligence - The new AI-generated risk intelligence feature is part of the Rapid7 Command Platform and is delivered through the Remediation Hub, providing security teams with actionable insights to prioritize remediation efforts [1][3] - AI-generated risk summaries allow organizations to quickly identify affected systems, real-world activity related to risks, and recommended next steps, thereby facilitating faster decision-making [3][4] - The integration of AI-driven context into risk summaries aims to improve alignment between security and IT teams, reducing the time to remediate vulnerabilities [3][6] Group 2: Vulnerability Intelligence Capabilities - Rapid7's Intelligence Hub now includes enhanced vulnerability intelligence capabilities that provide curated, real-world threat context for exploited CVEs, enabling effective prioritization of remediation efforts [4][5] - The vulnerability intelligence features are designed to filter out irrelevant alerts, focusing on vulnerabilities that pose actual risks to organizations [4][5] - Curated CVE profiles leverage data from Rapid7 Labs and other sources to support adversary-aware prioritization and mitigation strategies for security teams [5] Group 3: Market Need and Response - The widening gap between detection and action in cybersecurity is a significant challenge, with 22% of enterprise security decision-makers citing a lack of comprehensive remediation prioritization strategies [2] - Rapid7's innovations are positioned to address the urgent need for faster and more intelligent decision-making in vulnerability remediation, helping organizations to focus on impactful actions [2][3] - The rollout of AI-generated risk summaries and vulnerability intelligence capabilities is scheduled for late November, indicating a timely response to market demands [6]

HALIFAX, Nova Scotia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN; OTCQB: ERFCF) (“Erdene” or the “Company”) will release its third quarter 2025 results on November 4, 2025, after market close. On November 5, 2025 at 10:00 am ET, Management will host a conference call and webcast to discuss these results. Details to participate are as follows: Canada & US toll-free: (+1) 800 717 1738Outside of Canada & US: (+1) 289 514 5100Webcast - HERE Investors may send in quest ...

Free calling/texting/data for customers in Jamaica, Turks and Caicos, and the Bahamas and free calling from the US to these countries until Nov 12 What you need to know: In response to Hurricane Melissa, Verizon is offering free wireless and landline calling to Jamaica, Turks and Caicos, and the Bahamas to help our customers connect with loved ones.Customers within Jamaica, Turks and Caicos, and the Bahamas will also receive waived calling, texting and data chargesThis applies to all consumer and small busi ...

Geneva, Switzerland, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Geneva, Switzerland, Oct. 29, 2025 (GLOBE NEWSWIRE) --SEALSQ Corp (Nasdaq: LAES), ("SEALSQ" or "Company"), a global leader in cybersecurity, semiconductor technology and post-quantum security solutions, today announce that, following the June 2025 strategic acquisition of a 28.3% equity stake in Wecan, the Swiss pioneer in digital compliance platforms for regulated institutions, Wecan’s founder, Vincent Pignon, has resumed his role as Chief Executive Of ...

Core Insights - PDS Biotechnology Corporation is seeking an expedited approval pathway from the FDA for its immunotherapy PDS0101 targeting HPV16-positive head and neck cancer, projected to be the most prevalent type of head and neck cancer in the US by the mid-2030s [1][2] Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on innovative cancer treatments, particularly through its lead program PDS0101, which is being developed in combination with standard immune checkpoint inhibitors [4] Clinical Trials - The VERSATILE-002 trial has shown promising results, reporting a median overall survival (mOS) of 39.3 months and a median progression-free survival (PFS) of 6.3 months, leading to a proposed amendment in the ongoing VERSATILE-003 trial to include PFS as an earlier primary endpoint [1][2][3] - The VERSATILE-002 trial is an open-label, multi-center Phase 2 study evaluating the safety and efficacy of PDS0101 in combination with pembrolizumab for patients with unresectable, recurrent, or metastatic HPV16-positive head and neck cancer [3] Regulatory Strategy - The company plans to meet with the FDA to discuss changes to the current trial protocol, aiming to shorten the trial duration by making PFS an earlier primary endpoint, which could facilitate an accelerated approval submission [1][2]